Duolingo, Inc. (DUOL)
Verdict history · DUOL
Every call Verdix has made on DUOL.
While a verdict holds, its return keeps accumulating from the day the call was made — it resets only when the verdict itself changes.
Click any date below to read that write-up
The prior WAIT hinged on two triggers: a BUY if price fell into the $90–$110 accumulation zone, or a SELL if DAU growth decelerated below 15%. Neither trigger fired—price rose 10% to $146.13 and DAU accelerated to 23%. Yet the verdict flipped to SELL because the rally carried the stock past every analyst target and above the panel's own valuation range, transforming a once-reasonable price into one where downside risk now dominates. The business remains wonderful; the problem is purely that the price ran away from any margin of safety.
See methodology for how verdicts are produced. Full track record →
The panel’s case against DUOL — and where they disagree.
The case against outweighs the case for at today's price.
NASDAQ · Consumer Internet / EdTech · 2026-08-22 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
SellLOW confidence
Why
A panel of six analytical voices—spanning value, growth, quality, and innovation frameworks—unanimously agrees Duolingo is a wonderful business but concludes the stock at $146.13 has run past every reasonable valuation anchor. The debate centers on whether Q2's user-growth acceleration was durable or promotional, with the next two quarters of organic DAU and bookings data set to resolve a split that currently lands at SELL with low conviction.Level to watch
Key support 128.58−12.0% from 146.13
Next catalyst
Pullback to the accumulation zone: A decline to $100–$110 would bring forward P/E to ~13x, align the stock with the analyst consensus target of $104.55, and restore the margin of safety that multiple panelists require to turn constructive.The panel's take
Verdict: SELL · Conviction: LOW · Last price: 146.13 · Changed from WAIT
Panel: 0 Bullish · 3 Neutral · 3 Bearish → SELL
What changed since 2026-08-15:
- Price: 132.83 → 146.13 (+10.01%)
- Panel: 0 of 5 → 0 of 6 now Bullish — composition also changed: added The Asymmetric Bargainer, The Disruptive-Innovation Seeker, The Quality Rationalist; removed The Moat Compounder, The Scuttlebutt Growth Investor
- Trigger: The SELL verdict flips to WAIT if price pulls back into $100–$110, where forward P/E normalizes to ~13x, multiple voices (The Quality Rationalist, The GARP Operator, The Asymmetric Bargainer) agree margin of safety returns, and the analyst consensus target of $104.55 provides a valuation floor. It flips directly to BUY if, additionally, Q3 and Q4 both print organic DAU growth above 20% with bookings growth re-accelerating above 15%, proving the Q2 Streak Revival was not a one-off sugar high.
- Verdict: WAIT → SELL
The prior WAIT hinged on two triggers: a BUY if price fell into the $90–$110 accumulation zone, or a SELL if DAU growth decelerated below 15%. Neither trigger fired—price rose 10% to $146.13 and DAU accelerated to 23%. Yet the verdict flipped to SELL because the rally carried the stock past every analyst target and above the panel's own valuation range, transforming a once-reasonable price into one where downside risk now dominates. The business remains wonderful; the problem is purely that the price ran away from any margin of safety.
The prior WAIT at $132.83 set a trigger to BUY at $90–$110 or SELL on DAU deceleration below 15%. Neither fired: price is $146, well above the buy zone, and DAU growth accelerated to 23% in Q2. Yet the verdict is now SELL—not because the trigger fired, but because price has vaulted past every analyst target (consensus $104.55, high $145) and the panel's own valuation work (The Intrinsic-Value Modeler $118, The Forensic Skeptic $85–100) says the stock is now priced above even the bull case. The three bearish voices are all valuation skeptics on an otherwise wonderful business; the neutrals are cautious not on the company but on the technical setup and price entry. The prior trigger's buy zone still stands—what flipped is that the stock ran away from it, creating downside risk that now dominates.
Key levels
Key levels · DUOL
USD · as of 2026-08-22Analyst consensus target 104.55 USD · range 81–145
Key support & resistance and analyst consensus — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
Key support sits at $128.58 (weekly EMA20, the floor of the current bounce—lose it and the counter-trend rally fails) and anchored at $121.05 (volume-profile POC on both monthly and weekly, the most-traded price in DUOL's history). The $100.87–$141.24 volume bin is the heaviest cluster and where price action is likely to consolidate. Key resistance is $166.12 (weekly EMA50, the first major test for the weekly rally and the level the technical scout named as the neutral-to-bullish trigger). Beyond that, $177–$183 bands the weekly EMA200 and the 50-month EMA, the zone where the monthly downtrend begins to seriously contest any advance. The analyst consensus target of $104.55 sits 28.5% below the current price—the stock is already above even the most bullish published target ($145).
What legendary investors think
We ran Duolingo, Inc. past a panel of 6 legendary investors' frameworks.
The panel · 6 investors
The Intrinsic-Value ModelerValuation/DCF⚫ NeutralLow
Signal: At 31x EV/EBITDA and a consensus analyst target of $104.55—well below the current $146.13—the stock already prices in the bull case of 25% revenue growth and 35% margins, leaving no margin of safety when even the most optimistic Wall Street target has been surpassed. Conviction: Conviction is dampened because the Q2 DAU acceleration had a one-time promotional component (Streak Revival brought back 8M lapsed users) and Q3 bookings guidance of ~8.9% growth signals a sharp re-deceleration, making the base-case 18% revenue CAGR assumption feel generous rather than conservative.
The GARP OperatorGrowth (GARP)🔴 BearishMed
Signal: The forward P/E of 18.6x looks reasonable in isolation, but the 3-year EPS CAGR forecast of -9.56% means the growth that justified this multiple is vanishing—a slowing fast-grower with a forward P/E above 18x and falling growth rates is a dangerous combination. Conviction: Confidence rises because management's own Q3 bookings guidance of 8.9% growth undercuts the Q2 acceleration narrative, the stock already trades above every published analyst target, and the monthly chart remains unequivocally in Stage 4 markdown—three independent signals pointing the same direction.
The Forensic SkepticContrarian/Forensic🔴 BearishMed
Signal: The stock at $146.13 sits above the highest published analyst target of $145 while carrying only $30.33 per share in net cash—the remaining $116 per share of market cap must be supported entirely by future earnings that are decelerating quarter by quarter. Conviction: Conviction is reinforced by the absence of insider buying during a 65% drawdown, the Q3 bookings guide of 8.9% that management itself set as a low bar, and a weighted intrinsic-value range of $85–$100 using normalized multiples—three facts that collectively make the bear case hard to dispute.
The Disruptive-Innovation SeekerDisruptive Innovation⚫ NeutralLow
Signal: Duolingo's AI-driven personalization and 84% user retention signal a genuine innovation platform in early adoption, but revenue growth has decelerated from 30%+ to 18% with Q3 bookings guided to just 8.9%, meaning the S-curve may be flattening faster than the premium multiple anticipates. Conviction: The neutral stance is held back by one contested dependency: whether the Q2 DAU acceleration was a durable AI-driven inflection or merely a promotional sugar high, and until Q3 and Q4 print organic growth above 20%, that question remains unresolved.
The Asymmetric BargainerContrarian/Deep Value⚫ NeutralLow
Signal: The business is a textbook cash-generating machine—net cash of $30/share, 72.7% gross margins, 34.4% ROE, and H1 2026 free cash flow of $226M—but the stock fails the Dhandho test because downside to the consensus target of $104.55 is 28% while upside to the most bullish target of $160 is only 9%, an inverted payoff structure. Conviction: A split in smart-money positioning (quant funds added while growth funds trimmed) and the wide 35-percentage-point gap between bull and bear analyst targets keep conviction pinned at neutral, since neither the clones nor the sell-side have settled which camp is right.
The Quality RationalistMental Models/Quality🔴 BearishMed
Signal: This is a wonderful business—founder-led, zero debt, 34.4% ROE, capex at 2% of revenue, and 84% user retention—but when a wonderful business trades above the highest analyst target on the Street and consensus implies 28% downside, the probabilities favor the house, not the buyer. Conviction: The bearish call gains conviction from three independent pillars: management's own Q3 bookings guide of 8.9% signals a re-deceleration, the monthly chart is still Stage 4 with MACD deeply negative, and the mid-cap subscription peer group trades at ~10x EBITDA versus DUOL's 31x—a premium that only sustained 25%+ organic growth could justify.
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
- All six voices agree the business itself is high-quality—asset-light, cash-rich ($1.42B net cash), high gross margins (72.7%), and no debt.
- All agree the Q2 DAU acceleration had a one-time promotional component (Streak Revival, 8M lapsed users) that makes the organic growth rate uncertain.
- All agree the Q3 bookings guidance of ~8.9% YoY growth is a sharp deceleration that undercuts any narrative of durable re-acceleration.
- All agree the stock at $146.13 offers no margin of safety—it trades above the highest published analyst target ($145) and well above the consensus average ($104.55).
- Five of six voices cite the monthly Stage 4 downtrend (price 25% below monthly EMA20) as a dominant technical headwind that the weekly bounce has not resolved.
The real debate
- The Quality Rationalist and The Forensic Skeptic see the premium multiple (31x EV/EBITDA vs peer ~10x) as inherently unsustainable for a decelerating grower, while The Asymmetric Bargainer notes that a forward P/E of 18.6x is not obviously expensive if growth stabilizes above 15%, making the valuation gap either a trap or an opportunity depending on the next two quarters.
- The Disruptive-Innovation Seeker treats the AI-driven personalization and 84% retention as evidence the S-curve may still have room to run, while The GARP Operator and The Intrinsic-Value Modeler read the same data as maturation signals—the 3-year EPS CAGR of -9.56% and Q3 guidance of 8.9% growth point to a business normalizing faster than the innovation thesis requires.
- The Asymmetric Bargainer highlights that quant funds added in Q1 while growth funds trimmed, creating a split in smart-money signals that leaves the direction of the next move genuinely unresolved, whereas The Forensic Skeptic views the absence of insider buying during a 65% drawdown as a clear negative signal management does not believe the turnaround thesis.
The question it comes down to: Is the Q2 DAU acceleration a durable inflection driven by AI-powered product improvements, or was it a one-time promotional sugar high that masks a structural deceleration toward mid-teens growth—and can the stock sustain a 31x EV/EBITDA multiple if it is the latter?
The bottom line
- Pullback to the accumulation zone: A decline to $100–$110 would bring forward P/E to ~13x, align the stock with the analyst consensus target of $104.55, and restore the margin of safety that multiple panelists require to turn constructive.
- Q3 bookings and DAU: If Q3 prints organic DAU growth above 20% and bookings growth above 15%—without reliance on Streak Revival or similar promotions—the bear thesis of a one-time Q2 sugar high collapses and the growth premium becomes defensible.
- Monthly close above $194.52: A monthly close above the 20-month EMA would end the Stage 4 markdown that every technical voice on the panel cites as the dominant headwind, flipping the trend-following objection from bearish to neutral.
- Insider buying to watch: Management has not bought stock during a 65% drawdown; any sustained insider buying program would signal that those closest to the business see the current price as undervalued, directly countering The Forensic Skeptic's key objection.
- Further out: Q4 confirms or denies: Two consecutive quarters of organic DAU growth above 20% paired with bookings re-acceleration above 15% would likely flip the SELL to BUY, since that pattern would prove Q2 was the start of a durable inflection rather than a promotional blip.
contact@verdixhq.com · Published 2026-08-22 · Prices as of 2026-08-22 · Time horizon: 3–12 months · Founder holds a direct position in DUOL · DUOL verdict history → · Methodology →
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
The panel also debated